奥克拉西提尼布中毒情况
Sara Lister1, Jessica Kielb Basile2, Colette Wegenast1
1ASPCA Animal Poison Control Center, Champaign, Illinois, USA.
概括
家庭物摄入大量可的oclacitinib (OC) 正在经历新的毒性征兆. 这包括胃肠道,心血管和中枢神经系统问题,以及急性损伤,肝毒性和死亡.
科学领域:
- 兽医毒理学 兽医毒理学
- 小动物医学 小动物医学
背景情况:
- 引入可口味的oclacitinib导致物摄入量增加.
- 这导致了以前未被观察到的家庭动物中毒症的迹象.
研究的目的:
- 在物中记录和描述与oclacitinib过量服用相关的毒性症状.
- 通知兽医专业人员关于oclacitinib毒性的潜在风险和临床表现.
主要方法:
- 关于物中毒oclacitinib报告的病例的回顾性审查.
- 关于迹象,症状和结果的临床数据收集.
主要成果:
- 报告的中毒包括胃肠道症状 (吐,腹,腹痛),心血管问题 (心律不整,低血压,新的心脏声) 和中枢神经系统症状 (昏迷,沉的思维,升高的睡眠膜).
- 其他重要发现包括急性损伤,肝毒性和狗和猫的死亡.
结论:
- 兽医医生应主动监测和治疗表现为过量服用oclacitinib的临床症状的物.
- 建议与中毒控制中心协商,并向制造商和FDA报告不良事件,以管理oclacitinib毒性.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
140
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
140
Anticholinesterase Agents: Poisoning and Treatment
742
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
742
Allergic Drug Reactions
792
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
792
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
152
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
87
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
87
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127


